Cystic fibrosis. The Lancet, vol.388, pp.2519-2550, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02299268
,
, Patients with Cystic Fibrosis Homozygous for Phe508del CFTR, vol.373, pp.220-251, 2015.
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. The Lancet Respiratory Medicine, vol.4, pp.617-643, 2016. ,
Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax, vol.70, pp.615-621, 2015. ,
Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm, Thorax, vol.71, issue.2, pp.185-191, 2016. ,
Predictive factors for lumacaftor/ivacaftor clinical response, Journal of Cystic Fibrosis, vol.18, issue.3, pp.368-74, 2019. ,
Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02451455
Scoring of chest CT in children with cystic fibrosis: state of the art, Pediatric Radiology, vol.44, issue.12, pp.1496-506, 2014. ,
The spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease, Thorax, vol.64, issue.10, pp.876-82, 2009. ,
High-resolution computed tomography in young patients with cystic fibrosis: Distribution of abnormalities and correlation with pulmonary function tests, The Journal of Pediatrics, vol.145, issue.1, pp.32-40, 2004. ,
Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor, European Respiratory Journal, vol.48, issue.1, pp.249-52, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01416766
Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation, Journal of Cystic Fibrosis, vol.14, issue.1, pp.84-93, 2015. ,
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine, vol.5, pp.557-67, 2017. ,
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine, vol.7, pp.325-360, 2019. ,
,
, Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del, N Engl J Med, vol.377, issue.21, pp.2013-2036, 2017.
, , p.445
, Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N Engl J Med, vol.379, issue.17, pp.1612-1632, 2018.
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N Engl J Med, vol.379, issue.17, pp.1599-611, 2018. ,
Triple CFTR Modulator Therapy for Cystic Fibrosis, N Engl J Med, vol.379, issue.17, pp.1671-1673, 2018. ,